Interferon-&lambda;3 polymorphisms in pegylated-interferon-&alpha; plus ribavirin therapy for genotype-2 chronic hepatitis C

doi:10.3748/wjg.v21.i13.3904

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6792)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

356

WORD

314

HTML

3193

Figures (1-3)

176

Tables (1-2)

147

Sum=4186

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

970

Download

1636

Sum=2606

Apr 7, 2015 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastroenterol. Apr 7, 2015; 21(13): 3904-3911
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3904

Table 1 Analysis of factors affecting rapid virologic response to pegylated interferon-α plus ribavirin combination therapy in patients infected with hepatitis C virus genotype 2

	RVR	non-RVR	RVR vs non-RVR (1: non-RVR/2: RVR)
			Univariate analysis	Multivariate analysis
			P value	OR	95%CI	P value
Baseline factors
Demographic data
Number of patients	111	69
Gender (1:male/2:female)	54/57	31/38	0.8705
Age (yr)	60 (18-76)	60 (18-80)	0.9623
Body weight (kg)	59.4 (35.6-90.9)	56.0 (37.0-104)	0.5154
Body mass index (kg/m²)	23.4 (17.1-31.2)	22.8 (15.2-34.8)	0.9645
Histological fibrosis of liver (F0/1/2/3/4/ND )¹	5/45/18/13/13/17	2/24/9/6/17/11
(F0-3/F4)	81/13	41/17	0.0202
Prior interferon and ribavirin treatment response
Naïve/Relapse/Non response	101/10/0	64/3/2	0.8577
Laboratory data
Genetic variation at rs8099917 (TT/TG or GG)	87/24	55/14	0.9800
HCV-RNA (log₁₀IU/mL)	5.5 (5.0-7.0)	6.4 (5.0-7.3)	< 0.0001	4.40	2.24-8.63 (per 1.0 log₁₀IU/mL)	< 0.0001
HCV Genotype (2a/2b/2a + 2b/ND)	69/23/2/17	29/34/2/4	0.0005
White blood cells (/μL)	4800 (2400-10300)	4700 (2000-10200)	0.5170
Hemoglobin (g/dL)	14.1(9.5-18.2)	13.8 (9.3-16.9)	0.1899
Platelets (× 10⁴/μL)	17.1 (4.8-34.1)	16.6 (5.5-34.1)	0.7993
Aspartate aminotransferase (IU/L)	48 (16-317)	48 (13-455)	0.6753
Alanine aminotransferase (IU/L)	57 (10-361)	56 (9-356)	0.9699
Gamma-glutamyl-transpeptitase (IU/L)	43 (7-719)	48 (9-331)	0.7526
Albumin (g/dL)	4.1 (3.2-5.0)	4.0 (2.9-4.8)	0.0029	0.13	0.04-0.42 (per 1.0 g/dL)	0.0006
Fasting total cholesterol (mg/dL)	170 (118-265)	173 (106-270)	0.8155
Fasting low density lipoprotein-cholesterol (mg/dL)	99 (45-158)	103 (40-181)	0.4186
Fasting plasma glucose (mg/dL)	99 (76-221)	100 (76-320)	0.2002
Homeostasis model assessment-Insulin Resistance	1.59 (0.56-10.83)	1.38 (0.79-6.88)	0.4722
Alpha-fetoprotein (ng/mL)	4.7 (1.6-193.6)	5.0 (1.0-130)	0.4101

¹Classified by METAVIR score. Data are expressed as number of patients or median (range); ND: Not done; HCV: Hepatitis C virus; RVR: Rapid virologic response.

Citation: Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C. World J Gastroenterol 2015; 21(13): 3904-3911
URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3904.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3904